A Multinational, Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS Trial
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- Organon and Co
- Enrollment
- 1392
- Primary Endpoint
- Crude Rate of Newly Diagnosed Cancer-Follow-up Primary Cohort
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this extension is to observe the incidence rates of cancer, total mortality, and mortality due to cancer over a 21 month follow-up period in patients from the SEAS trial (2004_050, MK0653A-043; NCT00092677).
Detailed Description
The SEAS Follow-up Study is a 21 month extension to the base protocol (2004_050, MK0653A-043; NCT00092677). The main objective of the extension is to observe the incidence rates of cancer, total mortality, and mortality due to cancer over a 21 month follow-up period (from 04-March 2008 to 31-December 2009) in patients from the SEAS clinical trial. The sources of study data will include data collected from national cancer and death registries as well as data from the original clinical trial. No patient visits will occur. National cancer and death registries exist in 5 of the 7 countries that participated in the base SEAS trial. At the time of Follow-up study initiation, accessing the registry data in Ireland was not feasible due to local regulations and Cancer and Death registries did not exist in Germany. As a result, data will be collected only for all SEAS patients known to be alive at the end of the base study originating from Sweden, Denmark, Norway, Finland, and the United Kingdom.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The cohort will include all patients from the five participating countries (Sweden, Denmark, Norway, Finland, and United Kingdom) who were randomized into the SEAS base study and who were known to be alive at the end of the base study
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Crude Rate of Newly Diagnosed Cancer-Follow-up Primary Cohort
Time Frame: up to 21 Months after the end of the SEAS (base) study
Any incidence of cancer reported during follow-up that was assessed by the Expert Review Committee to be a new case of cancer. The crude new cancer rates for each arm were calculated as follows: Number of participants in the arm was multiplied by the Duration of Follow-up (days) and divided by 365 (days per year) to establish the Total Participant-years for the arm. The Number of New Cancers reported was then divided by the Total Participant-years and the resultant quotient was then multiplied by 100 to determine the Crude New Cancer Rate.
Secondary Outcomes
- Crude Rate of Death Due to Cancer - Follow-up Primary Cohort(up to 21 Months after the end of the base study)
- Crude Rate of Death (Any Cause) - Follow-up Total Cohort(up to 21 Months after the end of the base study)